Cargando…

A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters

Molecular farming of vaccines has been heralded as a cheap, safe and scalable production platform. In reality, however, differences in the plant biosynthetic machinery, compared to mammalian cells, can complicate the production of viral glycoproteins. Remodelling the secretory pathway presents an op...

Descripción completa

Detalles Bibliográficos
Autores principales: Margolin, Emmanuel, Schäfer, Georgia, Allen, Joel D., Gers, Sophette, Woodward, Jeremy, Sutherland, Andrew D., Blumenthal, Melissa, Meyers, Ann, Shaw, Megan L., Preiser, Wolfgang, Strasser, Richard, Crispin, Max, Williamson, Anna-Lise, Rybicki, Edward P., Chapman, Ros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028082/
https://www.ncbi.nlm.nih.gov/pubmed/36959936
http://dx.doi.org/10.3389/fpls.2023.1146234
_version_ 1784909862422970368
author Margolin, Emmanuel
Schäfer, Georgia
Allen, Joel D.
Gers, Sophette
Woodward, Jeremy
Sutherland, Andrew D.
Blumenthal, Melissa
Meyers, Ann
Shaw, Megan L.
Preiser, Wolfgang
Strasser, Richard
Crispin, Max
Williamson, Anna-Lise
Rybicki, Edward P.
Chapman, Ros
author_facet Margolin, Emmanuel
Schäfer, Georgia
Allen, Joel D.
Gers, Sophette
Woodward, Jeremy
Sutherland, Andrew D.
Blumenthal, Melissa
Meyers, Ann
Shaw, Megan L.
Preiser, Wolfgang
Strasser, Richard
Crispin, Max
Williamson, Anna-Lise
Rybicki, Edward P.
Chapman, Ros
author_sort Margolin, Emmanuel
collection PubMed
description Molecular farming of vaccines has been heralded as a cheap, safe and scalable production platform. In reality, however, differences in the plant biosynthetic machinery, compared to mammalian cells, can complicate the production of viral glycoproteins. Remodelling the secretory pathway presents an opportunity to support key post-translational modifications, and to tailor aspects of glycosylation and glycosylation-directed folding. In this study, we applied an integrated host and glyco-engineering approach, NXS/T Generation™, to produce a SARS-CoV-2 prefusion spike trimer in Nicotiana benthamiana as a model antigen from an emerging virus. The size exclusion-purified protein exhibited a characteristic prefusion structure when viewed by transmission electron microscopy, and this was indistinguishable from the equivalent mammalian cell-produced antigen. The plant-produced protein was decorated with under-processed oligomannose N-glycans and exhibited a site occupancy that was comparable to the equivalent protein produced in mammalian cell culture. Complex-type glycans were almost entirely absent from the plant-derived material, which contrasted against the predominantly mature, complex glycans that were observed on the mammalian cell culture-derived protein. The plant-derived antigen elicited neutralizing antibodies against both the matched Wuhan and heterologous Delta SARS-CoV-2 variants in immunized hamsters, although titres were lower than those induced by the comparator mammalian antigen. Animals vaccinated with the plant-derived antigen exhibited reduced viral loads following challenge, as well as significant protection from SARS-CoV-2 disease as evidenced by reduced lung pathology, lower viral loads and protection from weight loss. Nonetheless, animals immunized with the mammalian cell-culture-derived protein were better protected in this challenge model suggesting that more faithfully reproducing the native glycoprotein structure and associated glycosylation of the antigen may be desirable.
format Online
Article
Text
id pubmed-10028082
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100280822023-03-22 A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters Margolin, Emmanuel Schäfer, Georgia Allen, Joel D. Gers, Sophette Woodward, Jeremy Sutherland, Andrew D. Blumenthal, Melissa Meyers, Ann Shaw, Megan L. Preiser, Wolfgang Strasser, Richard Crispin, Max Williamson, Anna-Lise Rybicki, Edward P. Chapman, Ros Front Plant Sci Plant Science Molecular farming of vaccines has been heralded as a cheap, safe and scalable production platform. In reality, however, differences in the plant biosynthetic machinery, compared to mammalian cells, can complicate the production of viral glycoproteins. Remodelling the secretory pathway presents an opportunity to support key post-translational modifications, and to tailor aspects of glycosylation and glycosylation-directed folding. In this study, we applied an integrated host and glyco-engineering approach, NXS/T Generation™, to produce a SARS-CoV-2 prefusion spike trimer in Nicotiana benthamiana as a model antigen from an emerging virus. The size exclusion-purified protein exhibited a characteristic prefusion structure when viewed by transmission electron microscopy, and this was indistinguishable from the equivalent mammalian cell-produced antigen. The plant-produced protein was decorated with under-processed oligomannose N-glycans and exhibited a site occupancy that was comparable to the equivalent protein produced in mammalian cell culture. Complex-type glycans were almost entirely absent from the plant-derived material, which contrasted against the predominantly mature, complex glycans that were observed on the mammalian cell culture-derived protein. The plant-derived antigen elicited neutralizing antibodies against both the matched Wuhan and heterologous Delta SARS-CoV-2 variants in immunized hamsters, although titres were lower than those induced by the comparator mammalian antigen. Animals vaccinated with the plant-derived antigen exhibited reduced viral loads following challenge, as well as significant protection from SARS-CoV-2 disease as evidenced by reduced lung pathology, lower viral loads and protection from weight loss. Nonetheless, animals immunized with the mammalian cell-culture-derived protein were better protected in this challenge model suggesting that more faithfully reproducing the native glycoprotein structure and associated glycosylation of the antigen may be desirable. Frontiers Media S.A. 2023-03-07 /pmc/articles/PMC10028082/ /pubmed/36959936 http://dx.doi.org/10.3389/fpls.2023.1146234 Text en Copyright © 2023 Margolin, Schäfer, Allen, Gers, Woodward, Sutherland, Blumenthal, Meyers, Shaw, Preiser, Strasser, Crispin, Williamson, Rybicki and Chapman https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Plant Science
Margolin, Emmanuel
Schäfer, Georgia
Allen, Joel D.
Gers, Sophette
Woodward, Jeremy
Sutherland, Andrew D.
Blumenthal, Melissa
Meyers, Ann
Shaw, Megan L.
Preiser, Wolfgang
Strasser, Richard
Crispin, Max
Williamson, Anna-Lise
Rybicki, Edward P.
Chapman, Ros
A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters
title A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters
title_full A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters
title_fullStr A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters
title_full_unstemmed A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters
title_short A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters
title_sort plant-produced sars-cov-2 spike protein elicits heterologous immunity in hamsters
topic Plant Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028082/
https://www.ncbi.nlm.nih.gov/pubmed/36959936
http://dx.doi.org/10.3389/fpls.2023.1146234
work_keys_str_mv AT margolinemmanuel aplantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters
AT schafergeorgia aplantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters
AT allenjoeld aplantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters
AT gerssophette aplantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters
AT woodwardjeremy aplantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters
AT sutherlandandrewd aplantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters
AT blumenthalmelissa aplantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters
AT meyersann aplantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters
AT shawmeganl aplantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters
AT preiserwolfgang aplantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters
AT strasserrichard aplantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters
AT crispinmax aplantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters
AT williamsonannalise aplantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters
AT rybickiedwardp aplantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters
AT chapmanros aplantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters
AT margolinemmanuel plantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters
AT schafergeorgia plantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters
AT allenjoeld plantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters
AT gerssophette plantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters
AT woodwardjeremy plantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters
AT sutherlandandrewd plantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters
AT blumenthalmelissa plantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters
AT meyersann plantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters
AT shawmeganl plantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters
AT preiserwolfgang plantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters
AT strasserrichard plantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters
AT crispinmax plantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters
AT williamsonannalise plantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters
AT rybickiedwardp plantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters
AT chapmanros plantproducedsarscov2spikeproteinelicitsheterologousimmunityinhamsters